| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Myristoylated alanine-rich C kinase substrate[1]
BIO-11006 acetate targets the MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein, which is involved in various cellular processes including cell adhesion, migration, and secretion. MARCKS is a substrate for protein kinase C (PKC) and plays a role in the regulation of the actin cytoskeleton. By inhibiting MARCKS function, BIO-11006 modulates inflammatory responses in the lung, particularly neutrophil recruitment and cytokine production. |
|---|---|
| ln Vitro |
In vitro, BIO-11006 is shown to inhibit MARCKS function, though specific cellular EC50 values are not detailed in available literature. The compound has been studied for its ability to reduce proinflammatory responses in lung epithelial cells and macrophages. It attenuates NF-kappaB activation and decreases expression of inflammatory mediators such as KC (IL-8 homolog) and TNF-alpha in response to lipopolysaccharide (LPS) stimulation.
|
| ln Vivo |
In mice given intratracheal injections of LPS, inhaled, aerosolized BIO-11006 acetate reverses the development of lung injury by attenuating LPS-induced neutrophil influx into the lung, activation of NF-κB, and production of the proinflammatory cytokines, KC and TNF-α [1].
In vivo, BIO-11006 acetate (inhaled, aerosolized formulation) attenuates LPS-induced neutrophil influx into the lung, activation of NF-kappaB, and expression of proinflammatory cytokines KC and TNF-alpha, thereby reversing the development of lung injury in mice instilled intratracheally with LPS. The compound demonstrates efficacy in reversing disease progression in this acute lung injury model, supporting its research application for ALI/ARDS. |
| Enzyme Assay |
Binding assays for BIO-11006 focus on its interaction with the MARCKS protein. Typically, these studies employ surface plasmon resonance (SPR) or fluorescence polarization techniques to measure the binding affinity between the peptide and the MARCKS effector domain. Alternatively, competitive binding assays using labeled MARCKS peptides and the compound can be performed to determine IC50 or Kd values, confirming direct protein-peptide interaction.
|
| Cell Assay |
Cellular experiments for BIO-11006 utilize LPS-stimulated lung epithelial cells or macrophage cell lines such as RAW 264.7 or THP-1 cells. Cells are treated with varying concentrations of BIO-11006 for a defined period (e.g., 24-48 hours), then stimulated with LPS to induce inflammation. Endpoints include measurement of NF-kappaB activation by luciferase reporter assay or immunoblotting, quantification of proinflammatory cytokines (TNF-alpha, IL-6, KC) by ELISA in culture supernatants, and assessment of cell viability by MTT assay.
|
| Animal Protocol |
Animal studies for BIO-11006 are typically conducted in a mouse model of LPS-induced acute lung injury. Mice receive an intratracheal instillation of LPS to trigger lung inflammation. BIO-11006 acetate (inhalation or aerosolized) is administered either prophylactically or therapeutically. Endpoints include bronchoalveolar lavage fluid (BALF) analysis for neutrophil count and cytokine levels, lung histopathology for injury scoring, and Western blotting for NF-kappaB pathway activation markers.
|
| ADME/Pharmacokinetics |
A drug-specific pharmacokinetic (PK) properties of BIO-11006 are not listed in typical product literature. Since BIO-11006 is a peptide, its distribution and metabolic stability are likely to be evaluated via assays such as plasma stability testing and in vivo sampling, but PK parameters like bioavailability, half-life, and clearance are not readily available in general product descriptions and would be found in specialized pharmacology studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for BIO-11006 are not extensively detailed in available product literature. The compound has been studied in mouse models of acute lung injury and has shown efficacy without reports of significant adverse effects in the published studies. Standard preclinical toxicology assessments including acute and repeated-dose toxicity would be required for therapeutic development. For research use, standard peptide handling precautions apply.
|
| References | |
| Additional Infomation |
BIO-11006 acetate (CAS 901117-03-1) has the molecular formula C46H75N13O15 and a molecular weight of 1050.17. It is a peptide analog of the MANS peptide and functions as a MARCKS inhibitor. The compound is administered by inhalation or aerosolization in mouse models. It is indicated for research on acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Clinical development status is not specified, but it is currently a research tool. It is for research use only and not for human therapy.
|
| Molecular Formula |
C48H79N13O17
|
|---|---|
| Molecular Weight |
1110.22
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL (~45.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 20 mg/mL (18.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9007 mL | 4.5036 mL | 9.0072 mL | |
| 5 mM | 0.1801 mL | 0.9007 mL | 1.8014 mL | |
| 10 mM | 0.0901 mL | 0.4504 mL | 0.9007 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
